Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas

Japanese Journal of Cancer Research

Volumn 89, Issue 2, 1998, Pages 214-220

  Kakehi, Yoshiyuki ^a   Özdemir, Enver ^a   Habuchi, Tomonori ^a   Yamabe, Hirohiko ^b   Hashimura, Takayuki ^c   Katsura, Yoshitaka ^c   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION HIMEJI MEDICAL CENTER   (Japan)

Author keywords

Chemosensitivity; mdm2; p53; Urothelial cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; ONCOPROTEIN; PROTEIN P53; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; DNA DAMAGE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

EID: 0031890635     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00551.x     Document Type: Article

References (31)

1. Sternberg, C. N., Yagoda, A., Scher, H.I., Watson, R. C., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Jr., Bander, N., Weiselberg, L. R., Geller, N., Hollander, P. S., Lipperman, R., Fair, W. and Whitmore, W. F., Jr. MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 139, 461-469 (1988).
2. Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G. and Kilbourn, R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol., 8, 1050-1055 (1990).
3. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49, 5870-5878 (1989).
4. Dive, C. and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64, 192-196 (1991).
5. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542 (1994).
6. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
7. Clarke, A. R., Purdie, C. A. and Harrison, D. J. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849-852 (1993).
8. Smith, M. L., Chen, I. T., Zhan, Q., Bae, I., Chen, C-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M. and Furnace, A. J., Jr. Interaction of the p53-regulated protein Gadd 45 with proliferating cell nuclear antigen. Science, 266, 1376-1380 (1994).
9. Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated trans-activation. Cell, 69, 1237-1245 (1992).
10. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E. and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86, 1325-1330 (1994).
11. Barbareschi, M., Girlando, S., Fellin, G., Graffer, U., Luciani, L. and Dalla Palma, P. Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol. Res., 22, 349-352 (1995).
12. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W.-J., Takahashi, R., Sugiyama, T. and Yoshida, O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst., 86, 1331-1335 (1994).
13. Özdemir, E., Kakehi, Y., Okuno, H., Habuchi, T., Okada, Y. and Yoshida, O. Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas. J. Urol., 158, 206-211 (1997).
14. Kondo, S., Barnett, G. H., Hara, H., Morimura, T. and Takeuchi, J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10, 2001-2006 (1995).
15. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen Schaub, L. B. and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291 (1994).
16. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810 (1994).
17. Waldman, T., Lengauer, C., Kinzler, K. W. and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713-716 (1996).
18. Koechli, O., Schaer, G. N., Seifert, B., Hornung, R., Haller, U., Eppenberger, U. and Mueller, H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet, 344, 1647-1648 (1994).
19. Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M. and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55, 5038-5042 (1995).
20. Sarkis, A. S., Bajorin, D .F., Reuter, V. E., Herr, H. W., Zhang, Z.-F., Schultz, P. K., Cordon-Curdo, C. and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13, 1384-1390 (1995).
21. Cote, R. J., Esrig, D., Groschen, S., Jones, P. A. and Skinner, D. p53 and treatment of bladder cancer. Nature, 385, 123-124 (1997).
22. Japanese Urological Association and the Japanese Society of Pathology. "General Rule for Clinical and Pathological Studies on Bladder Cancer," 2nd Ed. (1993). Kanahara Co., Tokyo.
23. Japanese Urological Association and the Japanese Society of Pathology. "General Rule for Clinical and Pathological Studies on Renal Pelvic and Ureteral Cancer," 1st Ed. (1990). Kanahara Co., Tokyo.
24. Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675-679 (1990).
25. Maestro, R., Dolcetti, R., Gasparotto, D., Doglioni, C., Pelucchi, S., Barzan, L., Grandi, E. and Boiocchi, M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 7, 1159-1166 (1992).
26. Sjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L. and Bergh, J. The p53 gene in breast cancer; prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88, 173-182 (1996).
27. Esrig, D., Spruck, C. H., 3rd, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A. and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143, 1389-1397 (1993).
28. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331, 1259-1264 (1994).
29. Habuchi, T., Takahashi, R., Yamada, H., Ogawa, O., Kakehi, Y., Ogura, K., Hamazaki, S., Toguchida, J., Ishizaki, K., Fujita, J., Sugiyama, T. and Yoshida, O. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res., 53, 3795-3799 (1993).
30. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T. and Terada, M. Frequent association of p53 gene mutations in invasive bladder cancer. Cancer Res., 52, 1393-1398 (1992).
31. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F. and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794-799 (1994).